TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05231122: Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Sponsor: Roswell Park Cancer Institute · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT05231122 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05231122 Rescue Dossier →